Effect_NN of_IN 5-Iodo-2'-Deoxyuridine_NP on_IN Vaccinia_NP Virus_NP (_( Orthopoxvirus_NP )_) Infections_NNS in_IN Mice_NNS There_EX is_VBZ a_DT concern_NN that_IN there_EX may_MD be_VB unregistered_JJ stocks_NNS of_IN smallpox_NN that_WDT can_MD be_VB used_VBN for_IN bioterrorism_NN or_CC biological_JJ warfare_NN ._SENT According_VBG to_TO the_DT WHO_WP Advisory_NP Committee_NP on_IN Variola_NP Research_NP ,_, there_EX is_VBZ a_DT need_NN to_TO develop_VB strategies_NNS to_TO treat_VB smallpox_NN infections_NNS should_MD they_PP reappear_VB ._SENT It_PP would_MD also_RB be_VB important_JJ to_TO have_VB an_DT effective_JJ drug_NN at_IN hand_NN for_IN the_DT treatment_NN of_IN monkeypox_JJ disease_NN in_IN humans_NNS ._SENT We_PP show_VBP here_RB that_IN 5-iodo-2'-deoxyuridine_NP (_( IDU_NP )_) is_VBZ a_DT potent_JJ inhibitor_NN of_IN vaccinia_NN virus_NN (_( VV_NP )_) replication_NN and_CC that_IN IDU_NP inhibits_VBZ VV_NP DNA_NP synthesis_NN in_IN a_DT dose-dependent_JJ way_NN ._SENT The_DT in_IN vivo_JJ protective_JJ effect_NN of_IN IDU_NP was_VBD assessed_VBN in_IN the_DT VV_NP tail_NN lesion_NN model_NN in_IN immunocompetent_JJ mice_NNS and_CC in_IN a_DT lethal_JJ model_NN for_IN VV_NP infection_NN in_IN SCID_NN (_( severe_JJ combined_JJ immune_JJ deficiency_NN )_) mice_NNS that_WDT had_VBD been_VBN infected_VBN either_RB intranasally_RB ,_, intraperitoneally_RB ,_, or_CC intravenously_RB ._SENT Subcutaneous_JJ treatment_NN with_IN IDU_NP at_IN 150_CD and_CC 100_CD mg/kg_NN of_IN body_NN weight_NN markedly_RB reduced_VBD the_DT number_NN of_IN tail_JJ lesions_NNS in_IN immunocompetent_JJ NMRI_NP mice_NNS ._SENT Untreated_JJ intranasally_RB VV-infected_JJ SCID_NN mice_NNS died_VBD at_IN 20.8_CD +-_NN 3.1_CD days_NNS after_IN infection_NN (_( mean_VB +-_JJ standard_JJ deviation_NN )_) ._SENT Treatment_NN with_IN IDU_NP (_( subcutaneously_RB ,_, 150_CD mg/kg/day_NN [_SYM from_IN day_NN 0_CD to_TO 4_CD ]_SYM and_CC 75_CD mg/kg/day_NN [_SYM from_IN day_NN 6_CD to_TO 11_CD ]_SYM )_) delayed-virus_NN induced_VBD mortality_NN by_IN 15_CD days_NNS (_( mean_JJ day_NN of_IN death_NN +-_NN standard_JJ deviation_NN ,_, 35.8_CD +-_NN 6.7_CD ;_: P_NN <_SYM 0.0001_CD )_) ._SENT This_DT protective_JJ effect_NN was_VBD associated_VBN with_IN (_( i_NP )_) an_DT improvement_NN of_IN lung_NN histology_NN and_CC (_( ii_NNS )_) a_DT marked_JJ reduction_NN in_IN lung_NN viral_JJ titers_NNS ._SENT IDU_NP also_RB delayed_VBD VV-induced_JJ mortality_NN when_WRB mice_NNS had_VBD either_RB been_VBN infected_VBN intraperitoneally_RB or_CC intravenously_RB ._SENT Even_RB when_WRB the_DT start_NN of_IN treatment_NN with_IN IDU_NP (_( in_IN intraperitoneally_RB VV-infected_JJ mice_NNS )_) was_VBD postponed_VBN until_IN 2_CD or_CC 4_CD days_NNS after_IN infection_NN ,_, an_DT important_JJ delay_NN in_IN virus-induced_JJ mortality_NN was_VBD noted_VBN ._SENT There_EX is_VBZ an_DT increasing_VBG concern_NN that_IN the_DT smallpox_NN virus_NN may_MD be_VB used_VBN for_IN biological_JJ or_CC terroristic_JJ purposes_NNS ._SENT All_DT vaccination_NN programs_NNS against_IN smallpox_NN were_VBD discontinued_VBN after_IN eradication_NN of_IN the_DT disease_NN ._SENT Virtually_RB all_DT children_NNS and_CC many_JJ adults_NNS are_VBP now_RB fully_RB susceptible_JJ to_TO smallpox_NN ._SENT There_EX is_VBZ only_RB a_DT very_RB limited_JJ stock_NN of_IN vaccine_NN available_JJ ,_, which_WDT may_MD not_RB have_VB been_VBN at_IN all_DT properly_RB stored_VBN or_CC monitored_VBN for_IN potency_NN ._SENT It_PP is_VBZ being_VBG studied_VBN whether_IN diluting_VBG (_( 1/5_CD or_CC 1/10_CD )_) the_DT remaining_VBG vaccine_NN stocks_NNS would_MD be_VB possible_JJ so_RB as_RB to_TO increase_VB the_DT number_NN of_IN vaccines_NNS available_JJ ._SENT Novel_NN stocks_NNS of_IN vaccine_NN are_VBP currently_RB being_VBG prepared_VBN ._SENT If_IN smallpox_NN were_VBD used_VBN in_IN an_DT act_NN of_IN terrorism_NN or_CC warfare_NN ,_, it_PP could_MD ,_, in_IN a_DT highly_RB mobile_JJ and_CC susceptible_JJ population_NN ,_, cause_VB a_DT real_JJ catastrophe_NN ._SENT A_DT World_NP Health_NP Organization_NP (_( WHO_WP )_) advisory_JJ committee_NN on_IN variola_NN recommended_VBN in_IN 1999_CD the_DT development_NN of_IN drugs_NNS to_TO treat_VB human_JJ smallpox_NN infections_NNS should_MD they_PP reappear_VB (_( press_NN release_NN WHO/77_JJ ,_, 10_CD December_NP 1999_CD )_) ._SENT Human_JJ infection_NN with_IN monkeypox_NN occurs_VBZ sporadically_RB in_IN parts_NNS of_IN Western_NP and_CC Central_NP Africa_NP ._SENT In_IN 1996_CD and_CC 1997_CD an_DT important_JJ outbreak_NN of_IN monkeypox_NN occurred_VBN in_IN humans_NNS in_IN the_DT Democratic_NP Republic_NP of_IN Congo_NP ._SENT Also_RB there_EX have_VBP recently_RB been_VBN more_JJR outbreaks_NNS of_IN monkeypox_JJ disease_NN in_IN humans_NNS ._SENT It_PP is_VBZ thus_RB also_RB important_JJ to_TO have_VB an_DT effective_JJ drug_NN at_IN hand_NN for_IN the_DT treatment_NN of_IN monkeypox_JJ disease_NN in_IN humans_NNS ._SENT Inhibitors_NNS of_IN orthopoxviruses_NNS are_VBP also_RB of_IN interest_NN for_IN the_DT treatment_NN of_IN molluscum_NN contagiosum_NN or_CC disseminated_VBN vaccinia_NN (_( ,_, ;_: J._NP C._NP Guillaume_NP ,_, P._NP Saiag_NP ,_, J._NP Wechsler_NP ,_, M._NP C._NP Lescs_NP ,_, and_CC J._NP C._NP Roujeau_NP ,_, Letter_NP ,_, Lancet_NP 337:1034-1035_CD ,_, 1991_CD )_) ._SENT We_PP reported_VBD earlier_RBR on_IN the_DT potent_JJ anti-vaccinia_NN virus_NN (_( anti-VV_NP )_) activity_NN of_IN the_DT acyclic_JJ nucleoside_NN phosphonate_NN analog_JJ cidofovir_NN ,_, both_CC in_IN immunocompetent_JJ and_CC immunodeficient_JJ mice_NNS ._SENT VV_NP belongs_VBZ ,_, akin_JJ to_TO smallpox_NN and_CC monkeypox_NN viruses_NNS ,_, to_TO the_DT orthopoxviruses_NNS and_CC represents_VBZ a_DT valuable_JJ surrogate_NN for_IN the_DT latter_JJ viruses_NNS ._SENT Our_PP$ findings_NNS on_IN the_DT activity_NN of_IN cidofovir_NN in_IN the_DT vaccinia_NN model_NN were_VBD corroborated_VBN by_IN the_DT recent_JJ observation_NN that_IN cidofovir_NP also_RB protects_VBZ mice_NNS from_IN a_DT lethal_JJ aerosolized_JJ or_CC intranasal_JJ cowpox_NN virus_NN or_CC VV_NP challenge_NN ,_, either_CC when_WRB given_VBN to_TO the_DT mice_NNS systemically_RB or_CC when_WRB they_PP are_VBP intranasally_RB infected_VBN ._SENT The_DT compound_NN was_VBD also_RB shown_VBN to_TO inhibit_VB in_IN vitro_NN the_DT replication_NN of_IN 31_CD different_JJ strains_NNS of_IN variola_NN (_( according_VBG to_TO reference_VB )_) and_CC to_TO rescue_VB nonhuman_NN primates_NNS from_IN large_JJ quantities_NNS (_( 1,000_CD 50_CD %_NN lethal_JJ doses_NNS )_) of_IN aerosolized_JJ monkeypox_NN (_( data_NNS not_RB shown_VBN in_IN reference_NN )_) ._SENT Cidofovir_NP has_VBZ also_RB proven_VBN highly_RB effective_JJ against_IN parapoxvirus_NN infections_NNS in_IN vitro_NN and_CC in_IN vivo_RB ,_, in_IN particular_JJ in_IN a_DT case_NN of_IN orf_NN in_IN an_DT immunocompromised_JJ patient_NN ,_, and_CC against_IN molluscum_NN contagiosum_NN (_( E._NP G._NP Davies_NP ,_, A._NP Thrasher_NP ,_, K._NP Lacey_NP ,_, and_CC J._NP Harper_NP ,_, Letter_NP ,_, Lancet_NP 353:2042_CD ,_, 1999_CD )_) ._SENT Recently_RB ,_, we_PP demonstrated_VBD that_IN the_DT acyclic_JJ nucleoside_NN analogue_NN 2-amino-7-[1,3-dihydroxy-2-propoxy)methyl]-purine_NP (_( S2242_NP )_) in_IN its_PP$ diacetyl_NN ester_NN prodrug_NN form_NN protected_VBN SCID_NN mice_NNS against_IN VV-induced_JJ mortality_NN ,_, when_WRB given_VBN orally_RB ._SENT Here_RB we_PP describe_VBP the_DT protective_JJ effect_NN of_IN 5'-iodo-2'-deoxyuridine_NP (_( IDU_NP )_) (_( under_IN the_DT trade_NN names_NNS Herpid_NP ,_, Stoxil_NP ,_, Idoxene_NP ,_, and_CC Virudox_NP )_) ,_, a_DT well-known_JJ inhibitor_NN of_IN herpesvirus_NN replication_NN ,_, against_IN VV_NP infections_NNS in_IN immunodeficient_JJ mice_NNS ._SENT Virus_NN ,_, cells_NNS ,_, and_CC compounds_NNS ._SENT |_SYM VV_NP (_( Copenhagen_NP strain_NN )_) was_VBD obtained_VBN from_IN the_DT Rijksenstofinrichting_NP (_( Brussels_NP ,_, Belgium_NP )_) ._SENT This_DT virus_NN was_VBD formerly_RB used_VBN in_IN Belgium_NP as_IN a_DT vaccine_NN against_IN smallpox_NN ._SENT Human_JJ embryonic_JJ lung_NN (_( HEL_NP )_) cells_NNS were_VBD obtained_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP ._SENT IDU_NP was_VBD obtained_VBN from_IN Sigma_NP (_( St._NP Louis_NP ,_, Mo._NP )_) ._SENT Cidofovir_NP was_VBD synthesized_VBN at_IN ,_, and_CC provided_VBD by_IN ,_, Gilead_NP Sciences_NPS (_( Foster_NP City_NP ,_, Calif._NP )_) ._SENT In_IN vitro_NN antiviral_JJ assays_NNS ._SENT |_SYM Cultures_NP of_IN HEL_NP cells_NNS grown_VBN in_IN 96-well_NN plates_NNS were_VBD infected_VBN for_IN 2_CD h_NN at_IN 37C_JJ with_IN 100_CD PFU_NP of_IN VV_NP ._SENT Following_VBG a_DT 2-h_JJ adsorption_NN period_NN ,_, the_DT virus_NN inoculum_NN was_VBD removed_VBN and_CC the_DT cultures_NNS were_VBD incubated_VBN at_IN 37C_JJ with_IN different_JJ dilutions_NNS of_IN the_DT test_NN compounds_NNS in_IN modified_JJ Eagle_NP medium_NN containing_VBG 2_CD %_NN fetal_JJ calf_NN serum_NN ._SENT At_IN 5_CD days_NNS postinfection_NN ,_, cultures_NNS were_VBD fixed_VBN with_IN 70_CD %_NN ethanol_NN and_CC stained_VBN with_IN a_DT 2_CD %_NN Giemsa_NP solution_NN ,_, and_CC virus-induced_JJ cytopathic_JJ effects_NNS (_( CPEs_NP )_) were_VBD recorded_VBN microscopically_RB ._SENT The_DT 50_CD %_NN effective_JJ concentration_NN (_( EC50_NP )_) was_VBD defined_VBN as_IN the_DT concentration_NN that_WDT causes_VBZ 50_CD %_NN inhibition_NN of_IN virus-induced_JJ CPE_NN ._SENT All_DT experiments_NNS represent_VBP mean_JJ values_NNS for_IN two_CD to_TO four_CD independent_JJ determinations_NNS ._SENT Cytotoxic_JJ and_CC cytostatic_JJ determinations_NNS ._SENT |_SYM Cytotoxicity_NN was_VBD assessed_VBN in_IN confluent_JJ HEL_NP cell_NN cultures_NNS that_WDT had_VBD been_VBN incubated_VBN for_IN 5_CD consecutive_JJ days_NNS with_IN serial_JJ dilutions_NNS of_IN the_DT test_NN compounds_NNS and_CC was_VBD monitored_VBN microscopically_RB or_CC by_IN means_NNS of_IN the_DT MTS_NP method_NN (_( Promega_NP )_) ._SENT The_DT tetrazolium_NN salt_NN MTS_NP [_SYM 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium_NN ]_SYM ,_, when_WRB applied_VBN to_TO living_VBG cells_NNS ,_, is_VBZ converted_VBN to_TO a_DT colored_VBN formazan_NN ._SENT The_DT cytostatic_JJ potential_NN of_IN the_DT compounds_NNS was_VBD assessed_VBN in_IN exponentially_RB growing_VBG HEL_NP cells_NNS ._SENT Briefly_RB ,_, HEL_NP cells_NNS were_VBD seeded_VBN in_IN 96-well_NN plates_NNS at_IN a_DT density_NN of_IN 4,000_CD cells_NNS per_IN well_RB ._SENT At_IN 6_CD to_TO 8_CD h_NN after_IN seeding_VBG ,_, the_DT cells_NNS were_VBD incubated_VBN with_IN serial_JJ dilutions_NNS of_IN the_DT test_NN compounds_NNS ._SENT Cultures_NNS were_VBD then_RB incubated_VBN for_IN 3_CD days_NNS ,_, at_IN which_WDT time_NN cell_NN proliferation_NN was_VBD determined_VBN by_IN the_DT MTS_NP method_NN (_( Promega_NP )_) ._SENT All_DT experiments_NNS are_VBP mean_JJ values_NNS for_IN two_CD to_TO four_CD independent_JJ determinations_NNS ._SENT Determination_NN of_IN viral_JJ DNA_NN levels_NNS ._SENT |_SYM Confluent_JJ cultures_NNS of_IN HEL_NP cells_NNS grown_VBN in_IN 25-cm2_JJ culture_NN flasks_NNS were_VBD inoculated_VBN with_IN VV_NP at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 0.2_CD for_IN 2_CD h._NN After_IN the_DT virus_NN had_VBD been_VBN removed_VBN ,_, cultures_NNS were_VBD either_RB treated_VBN with_IN the_DT test_NN compounds_NNS or_CC left_VBD untreated_JJ ._SENT At_IN day_NN 5_CD postinfection_NN ,_, at_IN which_WDT time_NN untreated_JJ infected_JJ cultures_NNS showed_VBD 100_CD %_NN CPE_NN ,_, cells_NNS were_VBD collected_VBN ,_, total_JJ cellular_JJ DNA_NN was_VBD extracted_VBN (_( Qiagen_NP blood_NN kit_NN )_) ,_, and_CC 10_CD mug_NN of_IN heat_NN denatured_VBD total_JJ cellular_JJ DNA_NN was_VBD blotted_VBN onto_IN a_DT nylon_NN membrane_NN (_( Hybond-N_NP ;_: Amersham_NP )_) ._SENT Following_VBG UV_NP cross-linking_NN ,_, prehybridization_NN was_VBD carried_VBN out_RP for_IN 1_CD h_NN at_IN 42C_JJ ._SENT A_DT digoxigenin-11-dUTP-labeled_JJ VV-specific_JJ probe_NN was_VBD generated_VBN as_IN described_VBN previously_RB ._SENT Hybridization_NN was_VBD carried_VBN out_RP for_IN 18_CD h_NN at_IN 42C_JJ with_IN 30_CD ng_NNS of_IN the_DT digoxigenin-11-dUTP_NN labeled_VBD probe_NN per_IN ml_NN ._SENT Following_NN washes_VBZ at_IN high_JJ and_CC low_JJ stringency_NN ,_, filters_NNS were_VBD incubated_VBN with_IN antidigoxigenin_NN antibody_NN conjugated_VBN with_IN alkaline_JJ phosphatase_NN (_( Boehringer_NP Mannheim_NP )_) ._SENT Detection_NN of_IN chemiluminescence_NN was_VBD performed_VBN by_IN standard_JJ methods_NNS ,_, and_CC films_NNS were_VBD scanned_VBN densitometrically_RB ._SENT Inoculation_NN ,_, treatment_NN ,_, and_CC evaluation_NN ._SENT |_SYM SCID_NN mice_NNS (_( bred_VBN at_IN the_DT Rega_NP Institute_NP under_IN specific-pathogen-free_JJ conditions_NNS )_) weighing_VBG about_RB 15_CD g_NN ,_, received_VBD inoculations_NNS intranasally_RB (_( following_NN sedation_NN )_) ,_, intravenously_RB (_( in_IN the_DT tail_JJ vein_NN )_) ,_, or_CC intraperitoneally_RB with_IN ,_, respectively_RB ,_, 20_CD ,_, 50_CD ,_, or_CC 200_CD mul_NN of_IN VV_NP (_( stock_NN of_IN similar105_NP PFU/ml_NP )_) ._SENT IDU_NP or_CC (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine_NP (_( HPMPC_NP )_) (_( cidofovir_NP )_) (_( for_IN treatment_NN schedules_NNS ,_, see_VBP Figures_NNS and_CC Tables_NP )_) was_VBD administered_VBN by_IN subcutaneous_JJ injection_NN (_( in_IN 0.2_CD ml_NN of_IN phosphate-buffered_JJ saline_NN )_) ._SENT Mortality_NN was_VBD recorded_VBN daily_RB ._SENT Naval_NP Medical_NP Research_NP Institute_NP (_( NMRI_NP )_) mice_NNS (_( Harlan_NP )_) weighing_VBG 17_CD to_TO 20_CD g_NN were_VBD inoculated_VBN in_IN the_DT tail_JJ vein_NN with_IN 4_CD x_SYM 103_CD PFU_NP of_IN VV_NP ._SENT Animals_NNS were_VBD treated_VBN by_IN subcutaneous_JJ injection_NN with_IN IDU_NP or_CC cidofovir_NP ._SENT The_DT number_NN of_IN tail_JJ lesions_NNS (_( vesiculae_NNS or_CC spots_NNS )_) was_VBD recorded_VBN at_IN days_NNS 6_CD and_CC 8_CD postinfection_NN ._SENT Statistically_RB significant_JJ differences_NNS in_IN the_DT mean_JJ day_NN of_IN death_NN (_( MDD_NP )_) (_( for_IN SCID_NN mice_NNS )_) or_CC the_DT number_NN of_IN tail_JJ lesions_NNS (_( for_IN NMRI_NP mice_NNS )_) was_VBD assessed_VBN by_IN means_NNS of_IN Student_NP 's_POS t_NN test_NN ._SENT The_DT animal_NN experiments_NNS were_VBD approved_VBN by_IN the_DT Ethical_JJ Committee_NP on_IN Vertebrate_NP Animals_NPS of_IN the_DT University_NP of_IN Leuven_NP ._SENT Determination_NN of_IN viral_JJ titers_NNS in_IN lungs_NNS ._SENT |_SYM At_IN day_NN 5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD ,_, or_CC 28_CD postinfection_NN ,_, lungs_NNS from_IN (_( for_IN each_DT time_NN point_NN )_) three_CD infected_JJ animals_NNS that_WDT had_VBD either_RB been_VBN treated_VBN with_IN IDU_NP or_CC HPMPC_NP or_CC that_WDT had_VBD been_VBN left_VBN untreated_JJ were_VBD dissected_VBN aseptically_RB ._SENT Tissue_NN homogenates_NNS (_( 10_CD %_NN ,_, wt/vol_NP )_) were_VBD prepared_VBN in_IN 2_CD %_NN modified_VBN Eagle_NP medium_NN and_CC were_VBD titrated_VBN (_( fivefold_JJ serial_NN dilutions_NNS )_) on_IN HEL_NP cells_NNS ._SENT Virus-induced_NP CPE_NP was_VBD recorded_VBN 5_CD days_NNS later_RBR ._SENT Histology_NN ._SENT |_SYM SCID_NN mice_NNS (_( similar15_JJ g_NN )_) that_WDT had_VBD been_VBN inoculated_VBN intranasally_RB with_IN VV_NP and_CC that_WDT had_VBD either_RB been_VBN left_VBN untreated_JJ or_CC that_WDT were_VBD treated_VBN subcutaneously_RB with_IN IDU_NP (_( 150_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD and_CC 75_CD mg/kg/day_NN from_IN day_NN 7_CD to_TO 11_CD )_) or_CC with_IN cidofovir_NN (_( at_IN 25_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD and_CC from_IN day_NN 7_CD to_TO 11_CD )_) were_VBD killed_VBN by_IN ether_NN anesthesia_NN ;_: lungs_NNS were_VBD dissected_VBN ,_, fixed_VBN (_( in_IN Bouin_NP )_) ,_, embedded_VBN in_IN paraffin_NN ,_, and_CC sectioned_VBN ._SENT Sections_NNS were_VBD stained_VBN with_IN hematoxylin-eosin_NN ._SENT In_IN vitro_NP anti-VV_NP activity_NN of_IN IDU_NP ._SENT |_SYM The_NP in_IN vitro_NP anti-VV_NP activities_NNS of_IN IDU_NP and_CC HPMPC_NP in_IN HEL_NP cells_NNS were_VBD compared_VBN ._SENT As_RB can_MD be_VB derived_VBN from_IN Fig._NN ,_, IDU_NP efficiently_RB inhibited_VBD VV-induced_NP CPE_NP formation_NN in_IN fibroblasts_NNS with_IN an_DT EC50_NP of_IN 0.4_CD mug/ml_NN ;_: the_DT EC50_NP of_IN HPMPC_NP was_VBD 2.6_CD mug/ml_NN ._SENT Viral_JJ DNA_NN synthesis_NN was_VBD monitored_VBN in_IN parallel_NN ._SENT A_DT dose-dependent_JJ inhibition_NN of_IN VV_NP DNA_NP synthesis_NN was_VBD observed_VBN ,_, with_IN EC50_NP values_NNS of_IN 0.3_CD mug/ml_NN for_IN both_DT IDU_NP and_CC HPMPC_NP ._SENT The_DT concentration_NN that_WDT causes_VBZ a_DT >=20_JJ %_NN reduction_NN in_IN cell_NN metabolism_NN (_( i.e._FW ,_, mitochondrial_JJ activity_NN )_) as_IN assessed_VBN by_IN the_DT MTS_NP method_NN was_VBD >100_JJ mug/ml_NN for_IN both_DT IDU_NP and_CC HPMPC_NP ._SENT Cytostatic_JJ effects_NNS of_IN HPMPC_NP and_CC IDU_NP were_VBD assessed_VBN in_IN uninfected_JJ exponentially_RB growing_VBG HEL_NP cells_NNS ._SENT The_DT 50_CD %_NN cytostatic_JJ concentrations_NNS of_IN IDU_NP and_CC HPMPC_NP were_VBD 69_CD +-_NN 36_CD and_CC 42_CD +-_NN 15_CD mug/ml_NN ,_, respectively_RB (_( means_NN +-_NN standard_NN deviations_NNS )_) ._SENT IDU_NP and_CC HPMPC_NP thus_RB yielded_VBD comparable_JJ selectivity_NN indices_NN (_( for_IN IDU_NP ,_, 230_CD ;_: for_IN HPMPC_NP ,_, 140_CD )_) when_WRB inhibition_NN of_IN viral_JJ DNA_NP synthesis_NN was_VBD used_VBN as_IN a_DT parameter_NN for_IN drug_NN efficacy_NN ._SENT Effect_NN of_IN IDU_NP on_IN VV-induced_NP tail_JJ lesions_NNS in_IN NMRI_NP mice_NNS ._SENT |_SYM Immunocompetent_NP NMRI_NP mice_NNS received_VBD treatment_NN with_IN IDU_NP at_IN 150_CD ,_, 100_CD ,_, or_CC 75_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 5_CD postinfection_NN ._SENT Typical_JJ tail_JJ lesions_NNS (_( first_JJ spots_NNS ,_, then_RB vesiculae_NNS )_) developed_VBN in_IN control_NN animals_NNS ._SENT The_DT protective_JJ effects_NNS of_IN IDU_NP and_CC HPMPC_NP were_VBD assessed_VBN at_IN day_NN 6_CD and_CC 8_CD postinfection_NN ._SENT On_IN day_NN 6_CD postinfection_NN ,_, no_DT vesiculae_NNS had_VBD developed_VBN on_IN the_DT tail_NN of_IN mice_NNS that_WDT had_VBD been_VBN treated_VBN with_IN IDU_NP at_IN 150_CD or_CC 100_CD mg/kg/day_NN ,_, whereas_IN all_DT untreated_JJ animals_NNS showed_VBD large_JJ numbers_NNS of_IN lesions_NNS on_IN the_DT tail_NN at_IN that_DT time_NN ._SENT IDU_NP still_RB resulted_VBD in_IN a_DT marked_JJ reduction_NN in_IN the_DT number_NN of_IN vesiculae_NNS on_IN day_NN 8_CD postinfection_NN ._SENT Treatment_NN with_IN IDU_NP at_IN 150_CD or_CC 100_CD mg/kg/day_NN resulted_VBN in_IN a_DT reduction_NN of_IN body_NN weight_NN of_IN ,_, respectively_RB ,_, 17_CD and_CC 6_CD %_NN on_IN day_NN 8_CD postinfection_NN (_( compared_VBN to_TO the_DT body_NN weight_NN at_IN the_DT start_NN of_IN the_DT experiment_NN )_) ._SENT Yet_RB ,_, the_DT general_JJ condition_NN of_IN the_DT animals_NNS appeared_VBD to_TO be_VB all_DT right_NN ._SENT Effect_NN of_IN IDU_NP on_IN VV-induced_NP morbidity_NN and_CC mortality_NN in_IN intranasally_RB infected_JJ SCID_NN mice_NNS ._SENT |_SYM SCID_NN mice_NNS that_WDT had_VBD been_VBN infected_VBN intranasally_RB became_VBD sick_JJ (_( ruffled_VBN fur_NN ,_, cachexia_NN )_) at_IN about_IN day_NN 14_CD postinfection_NN and_CC died_VBD at_IN 20_CD days_NNS postinfection_NN (_( MDD_JJ +-_NN standard_NN deviation_NN ,_, 20.8_CD +-_NN 3.1_CD )_) ._SENT When_WRB IDU_NP was_VBD administered_VBN subcutaneously_RB (_( 150_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD and_CC 75_CD mg/kg/day_NN from_IN day_NN 7_CD to_TO 11_CD )_) ,_, virus-induced_JJ mortality_NN was_VBD delayed_VBN by_IN 15_CD days_NNS (_( MDD_NP ,_, 35.8_CD +-_NN 6.7_CD ;_: p_NN <_SYM 0.00005_CD )_) ._SENT This_DT particular_JJ dosing_VBG schedule_NN allowed_VBD an_DT "_`` aggressive_JJ "_'' induction_NN dose_NN with_IN IDU_NP ,_, followed_VBN by_IN a_DT lower_JJR dosage_NN that_WDT was_VBD also_RB effective_JJ but_CC that_WDT had_VBD less_JJR of_IN an_DT effect_NN on_IN body_NN weight_NN ._SENT HPMPC_NP ,_, which_WDT was_VBD included_VBN as_IN a_DT reference_NN compound_NN at_IN 25_CD mg/kg/day_NN (_( same_JJ treatment_NN schedule_NN as_IN for_IN IDU_NP )_) ,_, delayed_VBN virus-induced_JJ mortality_NN by_IN 38_CD days_NNS (_( MDD_NP ,_, 55_CD +-_NN 5.9_CD )_) ._SENT In_IN a_DT parallel_JJ set_NN of_IN experiments_NNS viral_JJ titers_NNS were_VBD measured_VBN in_IN the_DT lungs_NNS of_IN treated_VBN and_CC untreated_JJ animals_NNS at_IN 5_CD ,_, 10_CD ,_, 15_CD ,_, 20_CD ,_, and_CC 28_CD days_NNS postinfection_NN (_( lungs_NNS of_IN three_CD animals_NNS were_VBD pooled_VBN )_) (_( data_NNS not_RB shown_VBN )_) ._SENT Titers_NNS increased_VBD steadily_RB in_IN the_DT lungs_NNS of_IN untreated_JJ animals_NNS from_IN day_NN 5_CD to_TO 15_CD postinfection_NN (_( 2.0_CD x_SYM 104_CD ,_, 6.0_CD x_SYM 104_CD ,_, and_CC 2.4_CD x_SYM 105_CD PFU/g_NP tissue_NN ,_, respectively_RB )_) ._SENT None_NN of_IN the_DT untreated_JJ animals_NNS survived_VBN after_IN day_NN 20_CD ._SENT In_IN the_DT IDU-treated_JJ animals_NNS ,_, viral_JJ titers_NNS were_VBD below_IN the_DT detection_NN limit_NN for_IN the_DT first_JJ 15_CD days_NNS ._SENT Some_DT infectious_JJ virus_NN was_VBD detected_VBN (_( similar250_NP PFU/g_NP tissue_NN )_) at_IN day_NN 20_CD ._SENT At_IN day_NN 28_CD postinfection_NN viral_JJ titers_NNS in_IN the_DT lungs_NNS were_VBD comparable_JJ (_( 2.8_CD x_SYM 105_CD PFU/ml_NN )_) to_TO titers_NNS in_IN the_DT lungs_NNS of_IN untreated_JJ animals_NNS at_IN day_NN 15_CD postinfection_NN ._SENT No_DT virus_NN was_VBD detectable_JJ in_IN HPMPC-treated_JJ animals_NNS up_RB to_TO 28_CD days_NNS postinfection_NN ._SENT Histologically_RB ,_, the_DT lungs_NNS of_IN intranasally_RB infected_JJ animals_NNS (_( at_IN 18_CD days_NNS postinfection_NN )_) showed_VBD a_DT patchy_JJ pattern_NN of_IN mild_JJ infiltration_NN of_IN alveolar_JJ walls_NNS by_IN neutrophils_NNS ._SENT Exudation_NN of_IN leukocytes_NNS into_IN alveolar_JJ spaces_NNS was_VBD minimal_JJ or_CC even_RB absent_JJ ._SENT Some_DT distal_JJ bronchioli_NN exhibited_VBD an_DT infiltration_NN of_IN the_DT mucosa_NN with_IN neutrophils_NNS ._SENT Lungs_NNS of_IN IDU-_NP or_CC HPMPC-treated_NP animals_NNS (_( at_IN 18_CD day_NN postinfection_NN )_) were_VBD histologically_RB indistinguishable_JJ from_IN lungs_NNS of_IN uninfected_JJ animals_NNS ._SENT Effect_NN of_IN IDU_NP on_IN VV-induced_NP mortality_NN in_IN intraperitoneally_RB or_CC intravenously_RB infected_JJ SCID_NN mice_NNS ._SENT |_SYM SCID_NN mice_NNS that_WDT had_VBD been_VBN inoculated_VBN intravenously_RB died_VBD at_IN about_RB 18_CD days_NNS postinfection_NN ._SENT Mortality_NN of_IN mice_NNS that_WDT had_VBD been_VBN treated_VBN with_IN IDU_NP at_IN 100_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD postinfection_NN and_CC at_IN 50_CD mg/kg/day_NN from_IN day_NN 7_CD to_TO 11_CD postinfection_NN was_VBD delayed_VBN by_IN 9_CD days_NNS ._SENT A_DT similar_JJ treatment_NN schedule_NN with_IN IDU_NP at_IN 50_CD mg/kg/day_NN resulted_VBN in_IN some_DT delay_NN in_IN virus-induced_JJ mortality_NN ,_, although_IN this_DT was_VBD statistically_RB not_RB significant_JJ (_( P_NN =_SYM 0.07_CD )_) ._SENT SCID_NN mice_NNS that_WDT had_VBD been_VBN infected_VBN intraperitoneally_RB ,_, and_CC that_WDT were_VBD left_VBN untreated_JJ ,_, died_VBD about_RB 1_CD month_NN postinfection_NN (_( MDD_NP ,_, 33.6_CD +-_NN 11.6_CD )_) ._SENT Treatment_NN with_IN IDU_NP at_IN 100_CD mg/kg/day_NN ,_, from_IN day_NN 0_CD to_TO 4_CD and_CC at_IN 50_CD mg/kg/day_NN from_IN day_NN 7_CD to_TO 11_CD ,_, day_NN 14_CD to_TO 18_CD ,_, day_NN 21_CD to_TO 25_CD ,_, and_CC day_NN 28_CD to_TO 32_CD delayed_JJ virus-induced_JJ mortality_NN by_IN almost_RB 1_CD month_NN (_( MDD_NP 60.4_CD +-_NN 20.6_CD )_) ._SENT Four_CD out_RB of_IN five_CD animals_NNS that_WDT had_VBD been_VBN treated_VBN with_IN IDU_NP at_IN 250_CD mg/kg_NN from_IN day_NN 0_CD to_TO 2_CD and_CC at_IN 100_CD mg/kg_NN from_IN day_NN 7_CD to_TO 11_CD ,_, day_NN 14_CD to_TO 18_CD ,_, day_NN 21_CD to_TO 25_CD ,_, and_CC day_NN 28_CD to_TO 32_CD survived_VBD the_DT infection_NN until_IN 135_CD days_NNS postinfection_NN ,_, at_IN which_WDT time_NN they_PP were_VBD sacrificed_VBN ._SENT No_DT virus_NN was_VBD recovered_VBN from_IN their_PP$ organs_NNS at_IN that_DT time_NN ._SENT Effect_NN of_IN delayed_JJ start_NN of_IN treatment_NN with_IN IDU_NP on_IN VV-induced_NP mortality_NN in_IN intraperitoneally_RB infected_JJ SCID_NN mice_NNS ._SENT |_SYM Even_RB when_WRB start_NN of_IN treatment_NN with_IN IDU_NP in_IN intraperitoneally_RB infected_JJ animals_NNS was_VBD delayed_VBN for_IN 2_CD or_CC 4_CD days_NNS postinfection_NN ,_, a_DT significant_JJ delay_NN in_IN virus-induced_JJ mortality_NN was_VBD still_RB noted_VBN ,_, although_IN the_DT protective_JJ effect_NN was_VBD less_RBR pronounced_VBN than_IN when_WRB treatment_NN was_VBD initiated_VBN at_IN the_DT day_NN of_IN infection_NN ._SENT When_WRB the_DT start_NN of_IN treatment_NN was_VBD delayed_VBN for_IN 7_CD days_NNS postinfection_NN ,_, no_DT significant_JJ delay_NN in_IN virus-induced_JJ mortality_NN was_VBD noted_VBN ._SENT Effect_NN of_IN IDU_NP treatment_NN on_IN growth_NN of_IN mice_NNS ._SENT |_SYM We_PP documented_VBD the_DT effect_NN of_IN treatment_NN with_IN IDU_NP on_IN the_DT growth_NN of_IN young_JJ SCID_NN mice_NNS ._SENT Mice_NNS received_VBD treatment_NN schedules_NNS as_RB used_VBN in_IN the_DT experiment_NN depicted_VBN in_IN Fig._NN and_CC in_IN the_DT experiments_NNS presented_VBN in_IN Tables_NP and_CC 3_CD ._SENT Treatment_NN with_IN IDU_NP at_IN 150_CD mg/kg/day_NN (_( day_NN 0_CD to_TO 4_CD )_) and_CC 75_CD mg/kg/day_NN (_( day_NN 7_CD to_TO 11_CD )_) had_VBD an_DT important_JJ effect_NN on_IN the_DT growth_NN of_IN the_DT animals_NNS ._SENT All_DT mice_NNS survived_VBD ,_, however_RB ,_, and_CC their_PP$ body_NN weight_NN slowly_RB increased_VBD following_VBG cessation_NN of_IN therapy_NN ._SENT Lower_JJR doses_NNS of_IN drugs_NNS that_WDT still_RB proved_VBD antivirally_RB active_JJ (_( Fig._NN ;_: Tables_NP and_NP )_) were_VBD well_RB tolerated_VBN and_CC resulted_VBN in_IN a_DT less-pronounced_JJ growth_NN retardation_NN ._SENT FIG._NN 1_CD ._SENT |_SYM In_IN vitro_NP anti-VV_NP activity_NN of_IN IDU_NP or_CC HPMPC_NP ,_, as_RB assessed_VBN by_IN recording_VBG virus-induced_JJ CPE_NN (_( upper_JJ panel_NN )_) or_CC viral_JJ DNA_NN synthesis_NN (_( lower_JJR panel_NN )_) ._SENT In_IN vitro_NP anti-VV_NP activity_NN of_IN IDU_NP or_CC HPMPC_NP ,_, as_RB assessed_VBN by_IN recording_VBG virus-induced_JJ CPE_NN (_( upper_JJ panel_NN )_) or_CC viral_JJ DNA_NN synthesis_NN (_( lower_JJR panel_NN )_) ._SENT Symbols_NNS :_: ,_, IDU_NP ;_: ,_, HPMPC_NP ._SENT All_DT data_NNS are_VBP mean_JJ values_NNS +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) for_IN two_CD to_TO four_CD independent_JJ determinations_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Effect_NN of_IN IDU_NP or_CC HPMPC_NP on_IN VV-induced_NP mortality_NN in_IN intranasally_RB infected_JJ SCID_NN mice_NNS ._SENT Effect_NN of_IN IDU_NP or_CC HPMPC_NP on_IN VV-induced_NP mortality_NN in_IN intranasally_RB infected_JJ SCID_NN mice_NNS ._SENT Data_NNS are_VBP mean_JJ values_NNS from_IN two_CD independent_JJ experiments_NNS ._SENT IDU_NP was_VBD administered_VBN subcutaneously_RB at_IN 150_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD and_CC at_IN 75_CD mg/kg/day_NN from_IN day_NN 7_CD to_TO 11_CD ,_, and_CC HPMPC_NP was_VBD administered_VBN at_IN 25_CD mg/kg/day_NN from_IN day_NN 0_CD to_TO 4_CD and_CC from_IN day_NN 7_CD to_TO 11_CD ._SENT Symbols_NNS :_: ,_, untreated_JJ controls_NNS (_( n_NN =_SYM 10_CD )_) ;_: *_SYM ,_, IDU-treated_JJ mice_NNS (_( n_NN =_SYM 10_CD )_) ;_: ,_, HPMPC-treated_JJ mice_NNS (_( n_NN =_SYM 9_CD )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Change_NP in_IN body_NN weight_NN of_IN SCID_NN mice_NNS (_( five_CD mice_NNS per_IN condition_NN )_) that_WDT had_VBD been_VBN treated_VBN twice_RB daily_JJ by_IN subcutaneous_JJ injection_NN with_IN IDU_NP using_VBG the_DT following_VBG treatment_NN schedules_NNS :_: IDU_NN at_IN 150_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC 75_CD mg/kg/day_NN on_IN days_NNS 7_CD to_TO 11_CD ,_, IDU_NP at_IN 100_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC 50_CD mg/kg/day_NN on_IN days_NNS 7_CD to_TO 11_CD (_( *_SYM )_) ,_, IDU_NP at_IN 75_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC on_IN days_NNS 7_CD to_TO 11_CD ;_: and_CC IDU_NP at_IN 50_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC on_IN days_NNS 7_CD to_TO 11_CD ._SENT Change_NN in_IN body_NN weight_NN of_IN SCID_NN mice_NNS (_( five_CD mice_NNS per_IN condition_NN )_) that_WDT had_VBD been_VBN treated_VBN twice_RB daily_JJ by_IN subcutaneous_JJ injection_NN with_IN IDU_NP using_VBG the_DT following_VBG treatment_NN schedules_NNS :_: IDU_NN at_IN 150_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC 75_CD mg/kg/day_NN on_IN days_NNS 7_CD to_TO 11_CD ,_, IDU_NP at_IN 100_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC 50_CD mg/kg/day_NN on_IN days_NNS 7_CD to_TO 11_CD (_( *_SYM )_) ,_, IDU_NP at_IN 75_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC on_IN days_NNS 7_CD to_TO 11_CD ;_: and_CC IDU_NP at_IN 50_CD mg/kg/day_NN on_IN days_NNS 0_CD to_TO 4_CD and_CC on_IN days_NNS 7_CD to_TO 11_CD ._SENT Data_NNS for_IN animals_NNS that_WDT were_VBD left_VBN untreated_JJ are_VBP also_RB indicated_VBN ._SENT TABLE_NN 1_CD |_SYM Effect_NN of_IN IDU_NP on_IN VV-induced_NP tail_JJ lesion_NN formation_NN in_IN intravenously_RB infected_JJ NMRI_NP mice_NNS TABLE_NP 2_CD |_SYM Effects_VBZ of_IN IDU_NP and_CC HPMPC_NP on_IN VV-induced_NP mortality_NN in_IN SCID_NN mice_NNS that_WDT had_VBD been_VBN infected_VBN intravenously_RB or_CC intraperitoneally_RB TABLE_NP 3_CD |_SYM Effect_NN of_IN delayed_JJ start_NN of_IN treatment_NN with_IN IDU_NP on_IN VV-induced_NP mortality_NN in_IN SCID_NN mice_NNS Until_IN the_DT introduction_NN of_IN vaccines_NNS in_IN the_DT early_JJ 1800s_NN ,_, poxviruses_NNS historically_RB caused_VBD serious_JJ disease_NN in_IN humans_NNS ._SENT The_DT last_JJ documented_VBN case_NN of_IN smallpox_NN occurred_VBN in_IN 1977_CD in_IN Somalia_NP ,_, and_CC the_DT WHO_WP declared_VBD that_IN smallpox_NN had_VBD been_VBN eradicated_VBN as_RB of_IN 1980_CD ._SENT Before_IN that_DT time_NN the_DT virus_NN had_VBD killed_VBN millions_NNS of_IN people_NNS ._SENT The_DT public_JJ health_NN threat_NN of_IN poxviruses_NNS has_VBZ recently_RB surfaced_VBN with_IN (_( i_NP )_) the_DT fear_NN for_IN terrorist_JJ attacks_NNS with_IN smallpox_NN and_CC (_( ii_NNS )_) the_DT observation_NN of_IN monkeypox_JJ infections_NNS in_IN humans_NNS ,_, especially_RB in_IN the_DT period_NN from_IN 1996_CD to_TO 1997_CD in_IN the_DT Democratic_NP Republic_NP of_IN Congo_NP (_( formerly_RB Zaire_NP )_) ._SENT Monkeypox_JJ infection_NN in_IN humans_NNS is_VBZ associated_VBN with_IN signs_NNS and_CC symptoms_NNS similar_JJ to_TO those_DT of_IN smallpox_NN ,_, including_VBG the_DT development_NN of_IN a_DT pustular_JJ rash_NN that_WDT is_VBZ clinically_RB indistinguishable_JJ from_IN smallpox_NN ._SENT The_DT infection_NN ,_, however_RB ,_, is_VBZ far_RB less_RBR lethal_JJ than_IN smallpox_NN ._SENT Starting_VBG in_IN 1977_CD ,_, the_DT number_NN of_IN laboratories_NNS holding_VBG stocks_NNS of_IN the_DT variola_NN virus_NN was_VBD reduced_VBN until_IN all_DT known_VBN stocks_NNS were_VBD consolidated_VBN in_IN only_JJ two_CD WHO_WP collaborating_VBG centers_NNS :_: the_DT Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP in_IN Atlanta_NP ,_, Ga._NP ,_, and_CC the_DT State_NP Research_NP Center_NP of_IN Virology_NP and_CC Biotechnology_NP (_( VECTOR_NP )_) laboratories_NNS in_IN Kotsovo_NP ,_, near_IN Novosibirsk_NP ,_, Russia_NP ._SENT Although_IN outlawed_VBN by_IN the_DT Biological_NP Weapons_NP Convention_NP in_IN 1972_CD ,_, there_EX is_VBZ a_DT serious_JJ concern_NN that_IN there_EX may_MD be_VB unregistered_JJ stocks_NNS of_IN smallpox_NN that_WDT can_MD be_VB used_VBN for_IN bioterrorism_NN or_CC biological_JJ warfare_NN ._SENT A_DT smallpox_NN outbreak_NN occurring_VBG today_NN in_IN a_DT highly_RB mobile_JJ and_CC susceptible_JJ population_NN would_MD likely_RB spread_VB widely_RB before_IN effective_JJ measures_NNS could_MD be_VB taken_VBN (_( ;_: C._NP Hooper_NP ,_, Letter_NP ,_, N._NP Engl_NP ._SENT J._NP Med_NP ._SENT 339:2027-2028_CD ,_, 1998_CD )_) ._SENT Since_IN there_EX is_VBZ no_DT approved_JJ treatment_NN for_IN smallpox_NN the_DT WHO_WP expert_NN committee_NN on_IN orthopoxvirus_NN infection_NN has_VBZ recommended_VBN that_IN specific_JJ antivirals_NNS for_IN the_DT treatment_NN of_IN poxviruses_NNS should_MD be_VB developed_VBN before_IN the_DT destruction_NN of_IN the_DT (_( officially_RB remaining_VBG )_) stocks_NNS of_IN variola_NN (_( press_NN release_NN WHO/77_JJ ,_, 10_CD December_NP 1999_CD )_) ._SENT We_PP previously_RB reported_VBD the_DT activity_NN of_IN some_DT nucleoside_NN phosphonate_NN analogs_NNS against_IN VV_NP replication_NN ._SENT The_DT prototype_NN compound_NN of_IN this_DT family_NN ,_, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine_NP (_( HPMPA_NP )_) ,_, was_VBD found_VBN to_TO exhibit_VB a_DT broad-spectrum_NN activity_NN against_IN a_DT wide_JJ variety_NN of_IN DNA_NN viruses_NNS ,_, including_VBG VV_NP ,_, and_CC inhibited_VBD the_DT development_NN of_IN tail_JJ lesions_NNS caused_VBN by_IN VV_NP ._SENT Cidofovir_NP (_( HPMPC_NP )_) ,_, which_WDT is_VBZ the_DT cytosine_NN counterpart_NN of_IN HPMPA_NP and_CC which_WDT has_VBZ been_VBN approved_VBN for_IN the_DT treatment_NN of_IN cytomegalovirus_NN retinitis_NN in_IN immunocompromised_JJ patients_NNS (_( i.e._FW ,_, patients_NNS with_IN AIDS_NP )_) ,_, has_VBZ an_DT activity_NN spectrum_NN comparable_JJ to_TO that_DT of_IN HPMPA_NP but_CC has_VBZ a_DT more-favorable_JJ toxicity_NN profile_NN in_IN vitro_NN and_CC in_IN vivo_RB (_( i.e._FW ,_, in_IN mice_NNS )_) ._SENT We_PP have_VBP demonstrated_VBN that_IN cidofovir_NN possesses_VBZ potent_JJ protective_JJ activity_NN against_IN a_DT lethal_JJ VV_NP infection_NN in_IN SCID_NN mice_NNS ._SENT Our_PP$ observations_NNS were_VBD corroborated_VBN by_IN the_DT findings_NNS of_IN Bray_NP and_CC colleagues_NNS who_WP demonstrated_VBD that_IN cidofovir_NN is_VBZ also_RB effective_JJ in_IN the_DT treatment_NN of_IN lethal_JJ aerosolized_JJ or_CC intranasal_JJ cowpox_NN virus_NN infections_NNS in_IN mice_NNS ._SENT In_IN the_DT same_JJ report_NN these_DT authors_NNS revealed_VBN (_( their_PP$ unpublished_JJ data_NNS )_) that_IN cidofovir_NN rescued_VBD monkeys_NNS that_WDT had_VBD received_VBN large_JJ quantities_NNS (_( 1,000_CD 50_CD %_NN lethal_JJ doses_NNS )_) of_IN aerosolized_JJ monkeypox_NN and_CC that_IN the_DT compound_NN was_VBD active_JJ in_IN vitro_NN against_IN several_JJ different_JJ strains_NNS of_IN smallpox_NN ._SENT The_DT antipoxvirus_NN activity_NN of_IN cidofovir_NN was_VBD also_RB further_RBR documented_VBN in_IN murine_JJ models_NNS ._SENT Recently_RB ,_, cidofovir-resistant_JJ strains_NNS of_IN camelpox_NN ,_, cowpox_NN ,_, and_CC monkeypox_NN viruses_NNS and_CC VV_NP were_VBD generated_VBN ._SENT Cidofovir_NP has_VBZ been_VBN shown_VBN to_TO result_VB in_IN complete_JJ regression_NN of_IN lesions_NNS associated_VBN with_IN poxviruses_NNS in_IN humans_NNS ,_, i.e._FW ,_, molluscum_JJ contagiosum_NN lesions_NNS (_( ,_, ;_: V._NP Ibarra_NP ,_, J._NP R._NP Blanco_NP ,_, J._NP A._NP Oteo_NP ,_, and_CC L._NP Rosel_NP ,_, Letter_NP ,_, Acta_NP Derm_NP ._SENT Venereol_NP ._SENT 80:315-316_CD ,_, 2000_CD )_) and_CC orf_NP (_( ecthyma_NN infections_NNS )_) in_IN an_DT immunodeficient_JJ patient_NN ._SENT Recently_RB ,_, we_PP demonstrated_VBD that_IN the_DT acyclic_JJ nucleoside_NN analogue_NN 2-amino-7-[1,3-dihydroxy-2-propoxy)methyl]purine_NP (_( S2242_NP )_) and_CC its_PP$ diacetylated_JJ oral_JJ prodrug_NN form_NN HOE961_NP (_( the_DT latter_NN when_WRB given_VBN orally_RB )_) elicit_VB potent_JJ activity_NN against_IN VV_NP infections_NNS in_IN both_DT immunocompetent_NN and_CC SCID_NN mice_NNS ._SENT There_EX were_VBD no_DT obvious_JJ side_NN effects_NNS associated_VBN with_IN this_DT treatment_NN ._SENT A_DT compound_NN that_WDT can_MD be_VB given_VBN orally_RB offers_VBZ ,_, particularly_RB for_IN the_DT treatment_NN of_IN poxvirus_NN infections_NNS ,_, an_DT advantage_NN over_IN compounds_NNS that_WDT must_MD be_VB given_VBN intravenously_RB ._SENT In_IN this_DT context_NN it_PP is_VBZ of_IN interest_NN to_TO mention_VB that_IN alkoxyalkyl_NN esters_NNS of_IN cidofovir_NN and_CC cyclic_JJ cidofovir_NN that_WDT may_MD have_VB an_DT improved_VBN oral_JJ bioavailability_NN profile_NN showed_VBD enhanced_VBN in_IN vitro_NN inhibition_NN of_IN orthopoxvirus_NN replication_NN ._SENT We_PP demonstrate_VBP here_RB that_IN the_DT antiherpetic_NN compound_NN IDU_NP (_( under_IN the_DT trade_NN names_NNS Herpid_NP ,_, Stoxil_NP ,_, Idoxene_NP ,_, and_CC Virudox_NP )_) is_VBZ able_JJ to_TO cause_VB an_DT important_JJ delay_NN in_IN VV-induced_JJ mortality_NN in_IN SCID_NN mice_NNS infected_VBN either_RB intranasally_RB ,_, intraperitoneally_RB ,_, or_CC intravenously_RB ._SENT The_DT protective_JJ activity_NN of_IN IDU_NP (_( and_CC that_IN of_IN HPMPC_NP )_) was_VBD also_RB reflected_VBN by_IN the_DT fact_NN that_IN lung_NN histology_NN in_IN drug-treated_JJ infected_JJ animals_NNS was_VBD normal_JJ (_( at_IN 18_CD days_NNS postinfection_NN )_) ,_, whereas_IN focal_JJ anomalies_NNS (_( similar_JJ to_TO those_DT described_VBN in_IN reference_NN )_) were_VBD noted_VBN in_IN the_DT untreated_JJ mice_NNS ._SENT The_DT lung_NN pathology_NN as_RB seen_VBN here_RB in_IN the_DT untreated_JJ mice_NNS is_VBZ not_RB as_RB severe_JJ as_IN the_DT pathology_NN reported_VBD in_IN the_DT vaccinia_NN model_NN employed_VBN by_IN Smee_NP and_CC colleagues_NNS ._SENT This_DT may_MD be_VB explained_VBN by_IN the_DT fact_NN that_IN in_IN the_DT present_JJ study_NN (_( i_NP )_) SCID_NN mice_NNS were_VBD used_VBN ,_, which_WDT lack_VBP functional_JJ T_NN and_CC B_NN cells_NNS and_CC which_WDT may_MD ,_, therefore_RB ,_, have_VBP less_RBR immunopathological_JJ involvement_NN (_( BALB/c_NP mice_NNS were_VBD used_VBN by_IN Smee_NP and_CC colleagues_NNS )_) and_CC (_( ii_NNS )_) a_DT strain_NN of_IN virus_NN was_VBD used_VBN that_WDT was_VBD different_JJ from_IN that_DT used_VBN by_IN Smee_NP and_CC colleagues_NNS ._SENT Also_RB in_IN the_DT cowpox_NN model_NN ,_, lung_NN pathology_NN was_VBD reported_VBN to_TO be_VB more_RBR severe_JJ than_IN that_WDT observed_VBD here_RB ._SENT The_DT protective_JJ activity_NN of_IN IDU_NP in_IN a_DT nonlethal_NN VV_NP pox_NN tail_NN lesion_NN model_NN was_VBD already_RB reported_VBN 25_CD years_NNS ago_RB ._SENT It_PP has_VBZ ,_, however_RB ,_, remained_VBD unknown_JJ whether_IN IDU_NP would_MD cause_VB protection_NN against_IN lethal_JJ orthopoxvirus_NN infections_NNS ._SENT Other_JJ compounds_NNS ,_, such_JJ as_IN trifluorothymidine_NN and_CC arabinofuranosyl_NN cytosine_NN have_VBP also_RB been_VBN reported_VBN to_TO cause_VB protection_NN in_IN the_DT VV_NP tail_NN lesion_NN model_NN or_CC in_IN the_DT VV_NP keratitis_NN model_NN in_IN rabbits_NNS ._SENT We_PP were_VBD ,_, however_RB ,_, not_RB able_JJ to_TO demonstrate_VB any_DT protective_JJ effect_NN with_IN either_DT arabinofuranosyl_NN cytosine_NN or_CC trifluorothymidine_NN against_IN lethal_JJ VV_NP infections_NNS in_IN SCID_NN mice_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT use_NN of_IN IDU_NP for_IN the_DT treatment_NN of_IN herpesvirus_NN infections_NNS is_VBZ restricted_VBN to_TO topical_JJ use_NN because_IN the_DT compound_NN was_VBD found_VBN to_TO be_VB too_RB toxic_JJ for_IN intravenous_JJ administration_NN ._SENT However_RB ,_, unlike_IN for_IN herpesvirus_NN infections_NNS ,_, there_EX is_VBZ only_RB one_CD compound_NN ,_, i.e._FW ,_, cidofovir_NP ,_, that_WDT could_MD possibly_RB be_VB used_VBN for_IN the_DT treatment_NN of_IN infections_NNS with_IN variola_NN ._SENT In_IN addition_NN ,_, as_RB mentioned_VBN above_IN ,_, it_PP has_VBZ now_RB been_VBN shown_VBN that_IN cidofovir-resistant_JJ strains_NNS can_MD be_VB generated_VBN ._SENT Deliberate_JJ release_NN of_IN cidofovir-resistant_JJ variola_NN strains_NNS would_MD leave_VB us_PP without_IN option_NN for_IN treatment_NN Although_IN one_CD should_MD aim_VB to_TO use_VB compounds_NNS that_WDT cause_VBP as_RB little_JJ as_IN possible_JJ adverse_JJ effects_NNS for_IN the_DT treatment_NN of_IN infections_NNS with_IN variola_NN ,_, the_DT fact_NN that_IN the_DT fatality_NN rate_NN associated_VBN with_IN smallpox_NN may_MD be_VB estimated_VBN at_IN 10_CD to_TO 50_CD %_NN (_( or_CC even_RB higher_JJR in_IN immunocompromised_JJ patients_NNS )_) may_MD possibly_RB justify_VB the_DT administration_NN of_IN a_DT relatively_RB toxic_JJ compound_NN for_IN a_DT short_JJ period_NN of_IN time_NN during_IN the_DT acute_JJ phase_NN of_IN the_DT infection_NN ._SENT Indeed_RB ,_, the_DT fatality_NN rate_NN of_IN smallpox_NN is_VBZ much_RB higher_JJR than_IN that_IN of_IN many_JJ oncological_JJ diseases_NNS for_IN which_WDT patients_NNS receive_VBP treatment_NN with_IN (_( relatively_RB )_) toxic_JJ substances_NNS ._SENT Further_JJR studies_NNS are_VBP warranted_VBN to_TO determine_VB whether_IN IDU_NP causes_VBZ protection_NN against_IN other_JJ orthopoxvirus_NN infections_NNS (_( i.e._FW ,_, smallpox_NN ,_, cowpox_NN ,_, monkeypox_NN ,_, camelpox_NP )_) in_IN vitro_NN and_CC in_IN vivo_RB ._SENT 